Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Debt (2020 - 2022)

Historic Total Debt for Anika Therapeutics (ANIK) over the last 7 years, with Q2 2022 value amounting to $4.3 million.

  • Anika Therapeutics' Total Debt fell 7442.21% to $4.3 million in Q2 2022 from the same period last year, while for Jun 2022 it was $4.3 million, marking a year-over-year decrease of 7442.21%. This contributed to the annual value of $4.3 million for FY2021, which is 6703.59% down from last year.
  • Latest data reveals that Anika Therapeutics reported Total Debt of $4.3 million as of Q2 2022, which was down 7442.21% from $4.3 million recorded in Q1 2022.
  • Anika Therapeutics' Total Debt's 5-year high stood at $50.0 million during Q2 2020, with a 5-year trough of $4.3 million in Q3 2021.
  • Over the past 3 years, Anika Therapeutics' median Total Debt value was $13.1 million (recorded in 2020), while the average stood at $16.3 million.
  • Data for Anika Therapeutics' Total Debt shows a peak YoY increase of 6626.0% (in 2021) and a maximum YoY decrease of 8280.0% (in 2021) over the last 5 years.
  • Quarter analysis of 3 years shows Anika Therapeutics' Total Debt stood at $13.1 million in 2020, then plummeted by 67.04% to $4.3 million in 2021, then changed by 0.0% to $4.3 million in 2022.
  • Its Total Debt stands at $4.3 million for Q2 2022, versus $4.3 million for Q1 2022 and $4.3 million for Q4 2021.